Jeetinder Singh Mahal, the Chief Operating Officer of $JSPR ($JSPR), sold 900 shares of the company on 12-12-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...
Jasper Therapeutics initiates Phase 1b/2a study of briquilimab for allergic asthma, targeting mast cell-driven diseases.Quiver AI SummaryJasper Therapeutics, Inc. has announced the dosing of the first...
As Jasper embarks on promising clinical trials and reports narrower losses, analysts remain bullish, setting ambitious price targets that could indicate substantial returns for investors.
Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth.